Navigation Links
Amsterdam Molecular Therapeutics Announces Negative Equity Position
Date:12/14/2011

atform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry.  AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of AMT only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business. AMT expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law. 


'/>"/>
SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
2. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
3. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
4. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
5. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
6. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
7. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
8. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
9. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
10. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
11. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... - The Fight Against Cancer Innovation Trust (FACIT) ... formation of Turnstone Biologics Inc. (Turnstone), a biotechnology ... harness the patient,s own immune system. ... Children,s Hospital of Eastern Ontario ... Institute for Cancer Research (OICR), the Ottawa Hospital ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Genedata, ... drug discovery and life science research, today announced ... the latest version of its enterprise solution for ... R&D enables more efficient discovery and development of ... to integrate and address protein optimization and developability ...
(Date:5/4/2015)... , May 4, 2015  Soligenix, Inc. (OTCQB: SNGX) ... products that address unmet medical needs in the areas ... will be presenting preclinical data from three of its ... Science and Technology Conference on May 12-14, 2015 to ... 701 Convention Plaza, St. Louis MO ...
(Date:5/4/2015)... 4, 2015 - New Massive ... students prepare for the United States Medical Licensing Examination ... scientific, technical and medical information products and services, announced ... Open Online Course) designed to help medical students prepare ... 1, the first and most daunting of the three ...
Breaking Biology Technology:Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 2Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 3Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 5Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 6Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 7Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 8Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 9Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 10Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 11Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 12Elsevier's Free MOOC Prepares Med Students for Licensing Exam 2Elsevier's Free MOOC Prepares Med Students for Licensing Exam 3
... Here are some troubleshooting hints that we have gathered , if your PCR yields no product:, , , ... , , , ... , , , ... , , , ...
... , , , , , Here are some troubleshooting hints that we have gathered , ... , , , ... , , , ... , , , , ...
... , , , , from rat lung, recombinant, , , , ... Catalog Number, Pack Size, , ... , , 3335402, ... , , , , , Package Inserts/Product , Instructions, ...
Cached Biology Technology:Trouble-shooting: No product 2Trouble-shooting: No product 3Trouble-shooting: No product 4Trouble-shooting: No product 5Trouble-shooting: Non-specific bands 2Trouble-shooting: Non-specific bands 3Trouble-shooting: Non-specific bands 4Trouble-shooting: Non-specific bands 5Trouble-shooting: Non-specific bands 6
(Date:4/21/2015)... , April 21, 2015 ... government policies are boosting access control systems market in ... According to a recently published report by TechSci Research ... ", the access control systems market in ... billion by 2020.The access control systems market in the ...
(Date:4/20/2015)... DUBAI , April 20, 2015 ... soars   Glenbeigh Records Management (GRM), ... contract with Dubai Islamic Bank. Having built up an impressive ... is now a leading player within the records management sector ... company expects to double is GCC staffbase and employ a ...
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... , This release is available in German ... area of climate research: for decades, scientists have been asking ... dust particles suspended in the atmosphere, enlarge the cloud cover ... no progress on this issue. Two scientists from the Max ...
... a major milestone in its three years of operation, RadMD ... for 150 clinical trials. , The most recent trial, ... was designed to test the efficacy of a new treatment ... support the primary analysis of Progression Free Survival based on ...
... scientists have received grants from the latest round of ... Recovery and Reinvestment Act (ARRA) of 2009. To date, ... million. The recent round of funding includes three highly ... the Challenge Grant competition ― only about 500 were ...
Cached Biology News:Do dust particles curb climate change? 2Do dust particles curb climate change? 3Do dust particles curb climate change? 4RadMD reaches 150th clinical trial 2Forsyth receives highly competitive challenge grants 2
... 5 ml. The same high performance ... columns for fast, reliable purification of ... 5/50 GL, XK 16/20, or other ... required.Extremely useful for exploiting either the ...
Luminometers...
...
... 200 IS System is ideal for developing ... reagents. This system contains the new, improved, ... Luminex. The user can design specific templates ... system has fully integrated graphing and data ...
Biology Products: